Report period | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|---|---|
End date of the reporting period | ||||||
Capitalization, $ | ||||||
Capitalization, $ | ||||||
Enterprise Value | ||||||
Book Value | ||||||
Shareholders Book Value | ||||||
Current liabilities | ||||||
Noncurrent liabilities | ||||||
Total liabilities | ||||||
Debt | ||||||
Cash and cash equivalents | ||||||
Net debt | ||||||
Assets | ||||||
Total ordinary shares | ||||||
Ordinary share price |
Ticker | Name | Type | Nominal value | ISIN | Price |
---|---|---|---|---|---|
MRKR:US | Marker Therapeutics | Common share | - | US57055L1070 | $4 |
Company name | Marker Therapeutics |
---|---|
Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
Business address | 3200 SOUTHWEST FREEWAY SUITE 2240 HOUSTON TX 77027 (713) 400-6400 |
Mailing address | 3200 SOUTHWEST FREEWAY SUITE 2240 HOUSTON TX 77027 |
Website | www.markertherapeutics.com |
Information disclosure | www.sec.gov |